SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
WOODGRIFT RANDEL WILLIAM

(Last) (First) (Middle)
100 ABBOTT PARK ROAD

(Street)
ABBOTT PARK IL 60064

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2019
3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Senior Vice President
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value 42,284 D
Common shares without par value 2,634(1) I Profit Sharing Trust
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy)(2) 02/20/2016 02/19/2025 Common shares 47,226 47 D
Option (right to buy)(3) 02/19/2017 02/18/2026 Common shares 83,333 38.4 D
Option (right to buy)(4) 02/17/2018 02/16/2027 Common shares 53,271 44.4 D
Option (right to buy)(5) 02/16/2019 02/15/2028 Common shares 69,605 59.94 D
Option (right to buy)(6) 02/22/2020 02/21/2029 Common shares 42,009 75.9 D
Explanation of Responses:
1. Balance in the Abbott Laboratories Stock Retirement Trust as of April 1, 2019.
2. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,742 on February 20, 2016, 15,742 on February 20, 2017, and 15,742 on February 20, 2018.
3. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 27,778 on February 19, 2017, 27,777 on February 19, 2018, and 27,778 on February 19, 2019.
4. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 17,757 and 17,757 became exercisable on February 17, 2018 and February 17, 2019, respectively, and 17,757 becomes exercisable on February 17, 2020.
5. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 23,202 became exercisable on February 16, 2019 and 23,201 and 23,202 becomes exercisable on February 16, 2020 and February 16, 2021, respectively.
6. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,003 on February 22, 2020, 14,003 on February 22, 2021, and 14,003 on February 22, 2022.
Jessica H. Paik, by power of attorney for Randel W. Woodgrift 04/03/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.